MEDP analyst estimates
Medpace (MEDP) analyst ratings, the average price target and its range, and every firm's latest call.
MEDP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 26, 2026 | BMO Capital | Medpace price target raised to $670 from $600 at BMO Capital | $670.00 |
| Oct 23, 2026 | Barclays | Medpace price target raised to $675 from $625 at Barclays | $675.00 |
| Oct 23, 2026 | Robert W. Baird | Medpace price target raised to $699 from $638 at Baird | $699.00 |
| Oct 23, 2026 | Mizuho Securities | Medpace price target raised to $730 from $700 at Mizuho | $730.00 |
| Oct 23, 2026 | UBS | Medpace price target raised to $700 from $673 at UBS | $700.00 |
| Oct 23, 2026 | Truist Financial | Medpace price target raised to $633 from $609 at Truist | $633.00 |
| Oct 7, 2026 | Barclays | Medpace price target raised to $625 from $600 at Barclays | $625.00 |
| Oct 7, 2026 | Mizuho Securities | Medpace price target raised to $700 from $665 at Mizuho | $700.00 |
| Sep 30, 2026 | UBS | Medpace resumed with a Neutral at UBS | $673.00 |
| Jul 24, 2026 | Robert W. Baird | Medpace price target raised to $624 from $547 at Baird | $624.00 |
| Jul 24, 2026 | BMO Capital | Medpace price target raised to $600 from $400 at BMO Capital | $600.00 |
| Jul 24, 2026 | Mizuho Securities | Medpace price target raised to $665 from $586 at Mizuho | $665.00 |
| Jul 24, 2026 | RBC Capital | Medpace price target raised to $692 from $484 at RBC Capital | $692.00 |
| Jul 23, 2026 | Leerink Partners | Medpace price target raised to $620 from $515 at Leerink | $620.00 |
| Jul 23, 2026 | Barclays | Medpace price target raised to $600 from $450 at Barclays | $600.00 |
- 10 firms rate MEDP: 2 buy, 8 hold, 0 sell.
- The average price target is $677.38 from 8 analysts, from $620.00 to $730.00.
Updated 2026-11-02 23:59 UTC